News

To combat the deadliest cancer in the world, investigators are learning its origin in at-risk patients to prevent it altogether.

Elevated cardiac troponins during hospitalization for influenza is associated with heightened risk of mortality after hospital discharge.

The past few years have seen emerging therapies, but the tragedies of 2020 have only amplified the healthcare inequalities associated with sickle cell care.

The first approved generic product for injection glucagon is also indicated for diagnostic use, when appropriate.

Influenza vaccination not only protects against the flu, but could lessen the severity of COVID-19.

The new federal asthma management guidelines mark the first update of the guidance since 2007.

Long-term outcomes in systemic lupus erythematosus have improved over time, but unmet needs include glucorticoid dependency and comorbidity burden.

Many patients with paradoxical vocal fold motion disorder are misdiagnosed, and instead believe they are dealing with asthma. But in many cases, their symptoms do not respond to therapies.

Point of care test-and-treat strategy for influenza improves efficiency of hospital triage and the clinical outcomes for patients with acute respiratory illness.

Tofacitinib-methotrexate trial extended as first randomized controlled trial of tofacitinib monotherapy for psoriatic arthritis.

Screening for hepatitis B virus has become the norm in patients about to undergo anti-tumor-necrosis factor α therapy, but new research finds the risk of reactivation of resolved infections is low.

Investigators from the University of California used a 3D silicone model of blood vessels in the brain to help elucidate this uncertain relationship.

A new study finds that higher AGE consumption is associated with increased odds of wheezing.

Fewer patients who received masitinib 4.5 mg/kg/day reached severe dementia stage.

Peter Lio, MD, discusses the various underlying causes behind itch.

The investigators called their findings the “opposite of what was expected.”

The 5 companies issued letters will have 15 days to submit a compliance plan.

The study reports that risk is greater in female patients and those born small for gestational age. However, overall causality is still uncertain.

The study authors wrote that understanding this phenomena can lead to determining the best therapeutic strategy with DAAs for certain patients.

Cabotegravir’s FDA breakthrough designation along with adaptive strategies being deployed are the biggest stories in HIV prevention this year.

The investigators measured a 3.5-month period before and after a policy was implemented to preserve hospital resources.

Despite the majority of frontline healthcare workers being women during the pandemic, television networks are infrequently featuring representative experts.

FibroGen will submit additional data for the New Drug Application.

The TARGET-NASH study seeks to shed light on treatment for NASH and NAFLD.

Experts offered their advice on 2 domains, topic identification and ranking of priorities, for pediatric research realms.

In this episode of Derm Discussions, Peter Lio, MD, discusses the difficulties treating itch as well as alternative—and perhaps surprising—therapeutic options.

A discussion on how the public is still concerned with flu shot myths, and how it may influence COVID-19 vaccination and overall mitigation.

Oseltamivir and zanamivir are compared in acute treatment of patients with severe influenza type-A H1N1 in China.

Cigarette and smokeless tobacco use continues to decrease rapidly among teenagers, but e-cigarette use is on the rise.

A discussion with a survey researcher on the 35% of US adults who state they won't get the vaccine this season.